Newsroom | 26900 results

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announced financial results for the second quarter ended June 30, 2025. “Through our combination with Akoya Biosciences, we have created a high-margin, high-throughput business with a compelling opportunity to deliver profitable growth in an expanded market,” said Masoud Toloue, CEO of Quanterix. “We have built a franchise that is gen...

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today reported business highlights and financial results for the second quarter ended June 30, 2025. “The data presented for all 117 patients enrolled in the registrational iMMagine-1 study continue to demonstrate anito-cel’s potential to be a life-changing therapy for mu...

ST. LOUIS--(BUSINESS WIRE)--C2N Diagnostics, LLC (“C2N”), a specialty diagnostics company with a vision to bring Clarity Through Innovation®, is reaching additional global healthcare providers eager to use its PrecivityAD2™ blood test to help diagnose Alzheimer’s disease. The PrecivityAD2™ blood test allows healthcare providers to determine the presence or absence of amyloid pathology, a known hallmark of Alzheimer’s disease, for patients being evaluated for cognitive complaints through a simpl...

ROOTSTOWN, Ohio--(BUSINESS WIRE)--BioMendics, a clinical-stage biopharmaceutical company focused on rare skin diseases, today announced the launch of the TAMES-02 clinical trial—a multicenter, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of TolaSure™, a first-in-class topical therapy for patients with generalized intermediate to severe Epidermolysis Bullosa Simplex (EB Simplex). EB Simplex is a rare, inherited skin disorder that causes painful blistering...

SAN FRANCISCO--(BUSINESS WIRE)--Planet Labs PBC (NYSE: PL), a leading provider of daily data and insights about Earth, today announced that it will participate in Morgan Stanley’s 13th Annual Laguna Conference, which is being held September 10-12, 2025. The company will be available for 1x1 meetings with investors. If interested in attending this event or scheduling a meeting with management, we recommend reaching out to your contact at Morgan Stanley to learn more. About Planet Planet is a lea...

ALISO VIEJO, Calif.--(BUSINESS WIRE)--ThinkBio.Ai® and UST Partner to Strengthen AI Enablement Capabilities for Biopharma and Healthcare Organizations....

LONDON--(BUSINESS WIRE)--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today reported its financial results for the second quarter ended June 30, 2025, and reviewed recent business highlights. “The updated data we presented at EHA this past quarter were highly encouraging and supportive of the therapeutic potential of divesiran as a first-in-class siRNA in PV,” said Craig Tooman, Pres...

AUSTIN, Texas--(BUSINESS WIRE)--ImmunoPrecise Antibodies Ltd. (NASDAQ : IPA) (« IPA » ou la « Société »), une entreprise de biothérapeutique offrant des solutions avancées en matière de biologiques et de découverte de médicaments, a annoncé aujourd’hui la vente de sa filiale basée aux Pays-Bas, ImmunoPrecise Antibodies (Europe) B.V. (« IPA Europe »), à AVS Bio, pour une valeur d’entreprise totale de 12 millions de dollars américains. AVS Bio, une entreprise du portefeuille d’Arlington Capital P...

VANCOUVER, British Columbia--(BUSINESS WIRE)--Quartz Imaging's latest PCI-AM Version 9 for Automated Microscopy Measurements is going to revolutionize the industry...

SAN DIEGO--(BUSINESS WIRE)--Innovative Industrial Properties, Inc. (NYSE: IIPR) (“IIP” or the “Company”), announced today that it entered into agreements to make an investment totaling up to $270 million into IQHQ, Inc. (“IQHQ”), a premier life science real estate platform with over $5 billion in total assets. The investment (the “Investment,” “Transaction,” or “Investment Transaction”) is comprised of two discrete investments that together are expected to earn a weighted average interest rate...